No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 555 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC... June 30, 2023 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung... August 5, 2021 Seven Ways an Occupational Therapist Can Help Patients Recovering From Breast... April 30, 2021 Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... January 22, 2025 Load more HOT NEWS Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2... EMA Recommends Granting a Marketing Authorisation for Decitabine / Cedazuridine Addressing the Challenges of Cancer Misinformation on Social Media Banking on breakthroughs for children and young people
